| DLI+IL-2后续治疗混合造血干细胞移植后的急性髓性白血病 |
| |
| 引用本文： | 王存邦,白海,欧英贤,潘耀柱,张茜,葸瑞,王小靖. DLI+IL-2后续治疗混合造血干细胞移植后的急性髓性白血病[J]. 中国医师进修杂志, 2006, 29(3): 9-11 |
| |
| 作者姓名： | 王存邦 白海 欧英贤 潘耀柱 张茜 葸瑞 王小靖 |
| |
| 作者单位： | 730050,兰州军区兰州医院全军血液病中心 |
| |
| 摘 要： | 目的探讨急性髓性白血病在经过混合造血干细胞移植(mixed-HSCT)后,应用供体淋巴细胞输注(DLI)+白介素-2(IL-2)作为后续免疫生物治疗措施的意义。方法8例急性髓性白血病患者在完全缓解期实施了Mixed-HSCT,于造血恢复后,给予DLI+IL-2治疗2~7次,并随访观察临床疗效。结果所有患者均获得造血重建且无移植物抗宿主病(GVHD)发生。经过1~5年观察,8例患者Mixed-HSCT后应用DLI+IL-2治疗的患者长期生存率为62.5%。结论Mixed-HSCT后应用DLI+IL-2,可能是有效提高长期生存率的免疫生物治疗措施之一。
|
| 关 键 词： | 混合造血干细胞移植 供者淋巴细胞输注 白介素-2 急性髓性白血病 |
| 修稿时间： | 2005-08-22 |
The clinical study of using DLI + IL- 2 after Mixed- HSCT in acute myelogenous leukemia |
| |
| WANG Cun-bang,BAI Hai,OU Ying-xian,PAN Yao-zhu,ZHANG Qian,XI Rui,WANG Xiao-jing. The clinical study of using DLI + IL- 2 after Mixed- HSCT in acute myelogenous leukemia[J]. Chinese Journal of Postgraduates of Medicine, 2006, 29(3): 9-11 |
| |
| Authors: | WANG Cun-bang BAI Hai OU Ying-xian PAN Yao-zhu ZHANG Qian XI Rui WANG Xiao-jing |
| |
| Abstract: | Objective To approach curative effect of using DLI +IL-2 as immunobiotherapy after Mixed-HSCT in acute myelogenous leukemia.MethodAfter times of chemotherapy,8 cases of patients with acute myelogenous leukemia received Mixed-HSCT,then were treated with DLI +IL-2 for 2-7 times.Observed clinical effect for 1 to 5 years.Result DFS in 8 cases of patients with acute myelogenous leukemia received Mixed-HSCT and treated with DLI +IL-2 for 2-7 times were 62.5%.There were no GVHD.Conclusion Immuno-biotherapy with DLI +IL-2 after Mixed-HSCT in patients of acute myelogenous leukemia may be a method to increase DFS efficiently. |
| |
| Keywords: | Mixed-HSCT DLI IL-2 Acute myelogenous leukemia |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
